top of page

The Role of Gut Microbiota in Inflammatory Bowel Disease (IBD)


Introduction

Inflammatory bowel disease, including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic condition characterised by inflammation of the gastrointestinal tract. Recent research has highlighted the importance of gut microbiota in the development and progression of IBD. Understanding the complex interactions between host immunity and gut microorganisms is essential for developing new therapeutic strategies (Frank et al., 2007). The gut microbiota plays a crucial role in maintaining gastrointestinal health and has been implicated in the pathogenesis of inflammatory bowel disease (IBD). This article examines the relationship between gut microbiota and IBD, covering background information, immunological context, mechanisms, benefits, disadvantages, and potential therapeutic interventions.


Background

The human gut harbours a diverse and dynamic population of microorganisms, collectively known as the gut microbiota. This community plays a vital role in digestion, nutrient absorption, and immune system modulation. Dysbiosis, or an imbalance in the gut microbiota, has been associated with various health conditions, including IBD (Tamboli et al., 2004). The gut-associated lymphoid tissue (GALT) is a critical component of the immune system, continuously interacting with gut microbiota. This interaction is crucial for maintaining immune homeostasis and preventing excessive inflammation. In IBD patients, an aberrant immune response to commensal microbiota contributes to chronic intestinal inflammation (Xavier and Podolsky, 2007).


Mechanisms of Gut Microbiota 

1. Microbial Dysbiosis: IBD patients often exhibit reduced microbial diversity and an imbalance in the composition of their gut microbiota. This dysbiosis can lead to a compromised gut barrier, increased permeability, and translocation of harmful bacteria, triggering an immune response (Kostic et al., 2014).

2. Immune Response: Dysregulated immune responses, including the activation of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12, are hallmarks of IBD. These cytokines perpetuate inflammation and tissue damage in the gut (Neurath, 2014).

3. Genetic Factors: Genetic susceptibility also plays a role in IBD. Variants in genes such as NOD2, which is involved in bacterial recognition and immune response, have been linked to an increased risk of developing IBD (Jostins et al., 2012).


How can gut microbiota help in IBS? 

  • Microbiota-Derived Metabolites: Short-chain fatty acids (SCFAs) produced by gut microbiota through fermentation of dietary fibres have anti-inflammatory properties and promote gut health (Rios-Covian et al., 2016).

  • Immune Regulation: Commensal bacteria help in the maturation and regulation of the immune system, preventing excessive inflammatory responses (Round and Mazmanian, 2009).


How can gut microbiota potentially worsen IBS? 

  • Dysbiosis-Related Inflammation: An imbalance in gut microbiota can lead to chronic inflammation, exacerbating IBD symptoms and contributing to disease progression.

  • Antibiotic Resistance: The use of antibiotics to manage dysbiosis can lead to the development of antibiotic-resistant strains, complicating treatment (Kennedy and Chevalier, 2011).


Therapeutic Interventions

1. Probiotics and Prebiotics: Probiotics (beneficial bacteria) and prebiotics (compounds that promote the growth of beneficial bacteria) have shown promise in restoring microbial balance and reducing IBD symptoms (Sartor, 2004).

2. Fecal Microbiota Transplantation (FMT): FMT involves the transfer of stool from a healthy donor to an IBD patient, aiming to restore a healthy microbiome. Preliminary studies suggest FMT can induce remission in some IBD patients (Moayyedi et al., 2015).

3. Dietary Modifications: Diet plays a significant role in shaping gut microbiota. Specific dietary interventions, such as the low FODMAP diet, can alleviate IBD symptoms by reducing fermentable substrates for pathogenic bacteria (Halmos et al., 2014).


Conclusion

The gut microbiota is integral to the pathogenesis and management of IBD. Understanding the intricate relationship between gut microorganisms and the immune system offers new avenues for therapeutic interventions. Continued research is essential to develop effective strategies to modulate the gut microbiota and improve outcomes for IBD patients.

 

Article prepared by: Chong Yuen Yeng, MBIOS R&D Associate 23/24


If you enjoyed this article, do sign up to become a part of our MBIOS family and receive our monthly newsletter along with many more resources in the link below.


 

References


  1. Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences, 104(34), 13780-13785.

  2. Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014). A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology, 146(1), 67-75.

  3. Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., ... & Parkes, M. (2012). Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491(7422), 119-124.

  4. Kennedy, K. J., & Chevalier, S. (2011). Antimicrobial resistance and the intestinal microbiota: A risk for the treatment of infectious diseases. Journal of Medical Microbiology, 60(Pt 12), 1661-1670.

  5. Kostic, A. D., Xavier, R. J., & Gevers, D. (2014). The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology, 146(6), 1489-1499.

  6. Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., ... & Marshall, J. K. (2015). Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology, 149(1), 102-109.

  7. Neurath, M. F. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 14(5), 329-342.

  8. Rios-Covian, D., Ruas-Madiedo, P., Margolles, A., Gueimonde, M., de Los Reyes-Gavilan, C. G., & Salazar, N. (2016). Intestinal short-chain fatty acids and their link with diet and human health. Frontiers in Microbiology, 7, 185.

  9. Round, J. L., & Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. Nature Reviews Immunology, 9(5), 313-323.

  10. Sartor, R. B. (2004). Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology, 126(6), 1620-1633.

  11. Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004). Dysbiosis in inflammatory bowel disease. Gut, 53(1), 1-4.

  12. Xavier, R. J., & Podolsky, D. K. (2007). Unravelling the pathogenesis of inflammatory bowel disease. Nature, 448(7152), 427-434.


Comments

Stay Up-To-Date with New Posts

Search By Tags

bottom of page